Buchumschlag

NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

© The European Society for Medical Oncology 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.comBackground: Nivolumab improves OS compared with docetaxel in previously treate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Socinski, Mark A. (VerfasserIn) , Steins, Martin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 13 October 2016
In: Annals of oncology
Year: 2016, Jahrgang: 27
ISSN:1569-8041
DOI:10.1093/annonc/mdw435.39
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw435.39
Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/LBA7_PR/2800548
Volltext
Verfasserangaben:M. Socinski, B. Creelan, L. Horn, M. Reck, L. Paz-Ares, M. Steins, E. Felip, M. van den Heuvel, T.E. Ciuleanu, F. Badin, N. Ready, T.J. N. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, W.J. Geese, P. Bhagavatheeswaran, A. Chen, D.P. Carbone
Beschreibung
Zusammenfassung:© The European Society for Medical Oncology 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.comBackground: Nivolumab improves OS compared with docetaxel in previously treated NSCLC. In a phase 1 study (CheckMate 012), nivolumab showed promising activity and manageable safety as monotherapy and in combination with ipilimumab in treatment naive advanced NSCLC. CheckMate 026 (NCT02041533), an open-label, randomized phase 3 study, evaluated the efficacy of nivolumab vs IC PT-DC as first-line therapy in stage IV/recurrent PD-L1-positive NSCLC.Methods: Patients with histologically confirmed and previously untreated stage IV or recurrent NSCLC, ECOG PS 0-1, and PD-L1 positivity were randomized 1:1 to receive nivolumab 3 mg/kg IV Q2W or IC PT-DC (histology-based) Q3W (up to 6 cycles) until disease progression or unacceptable toxicity. Patients with EGFR/ALK mutations sensitive to targeted therapy were excluded. Patients on IC PT-DC...
Beschreibung:Gesehen am 10.11.2017
Beschreibung:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdw435.39

Ähnliche Einträge